View Cart  

Biogen’s Hemophilia A Candidate Clears Late-Stage Trial, Analysts Question Dosing Advantage

A A
Biogen Idec’s positive Phase III results for its hemophilia A clotting factor candidate are pushing the company toward a U.S. filing in the first half of 2013.

To View This Article:

Login

Subscribe To Drug Industry Daily